SABCS and ASH findings: palbociclib improves PFS in HR+, HER2+ breast cancer, cilta-cel achieves 100% CR in smoldering MM, and selinexor with ruxolitinib aids myelofibrosis.

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase ...

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic ...

Panelist discusses how pivotal studies led to the approval of teclistamab in patients with less refractory multiple myeloma; ...

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple ...

In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma ...

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients ...